TKNO Overview

Alpha Teknova, Inc. is a producer of critical reagents for the discovery, development, and commercialization of novel therapies, vaccines, and molecular diagnostics. The Company offers three primary product types: pre-poured media plates for cell growth and cloning; liquid microbial culture media and supplements for cellular expansion, and molecular biology reagents for sample manipulation, resuspension, and purification. It offers a range of standard and specialty pre-poured media plates for a variety of applications including bacteria, fungi, and nematode growth. Its two primary product categories include Lab Essentials and Clinical Solutions. Its core Lab Essentials products consist of commonly used catalog solutions and customer-specified formulations. Its Clinical Solutions products are custom products used in the development and production of protein therapies, gene therapies, mRNA vaccines, and diagnostic kits.

Wall Street analysts forecast TKNO stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for TKNO is7.00 USD with a low forecast of 7.00 USD and a high forecast of 7.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

Alpha Teknova Inc revenue for the last quarter amounts to 11.08M USD, increased 13.09

Alpha Teknova Inc. EPS for the last quarter amounts to -0.08 USD, decreased -11.11

Alpha Teknova Inc (TKNO) has 158 emplpoyees as of June 20 2026.

Today TKNO has the market capitalization of 280.94M USD.